## Michele Gilio

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7760543/publications.pdf

Version: 2024-02-01

794141 840119 20 410 11 19 citations h-index g-index papers 20 20 20 806 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis. Rheumatology, 2022, 61, 2054-2062.	0.9	4
2	Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine. Internal and Emergency Medicine, 2022, , $1.$	1.0	11
3	The role of adalimumab in the treatment of heart block in HLA-B27-associated disease: a case description. Internal and Emergency Medicine, 2020, 15, 159-161.	1.0	O
4	Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort. Scientific Reports, 2019, 9, 2177.	1.6	20
5	Diffuse Idiopathic Skeletal Hyperostosis in an HLA-B27–Positive Subject. Journal of Clinical Rheumatology, 2019, 25, e94-e98.	0.5	2
6	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews, 2019, 18, 93-106.	2.5	101
7	A step towards standardization: A method for end-point titer determination by fluorescence index of an automated microscope. End-point titer determination by fluorescence index. Journal of Immunological Methods, 2018, 456, 67-71.	0.6	8
8	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. Advances in Therapy, 2018, 35, 545-562.	1.3	16
9	Safety of treatment options for spondyloarthritis: a narrative review. Expert Opinion on Drug Safety, 2018, 17, 475-486.	1.0	20
10	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Annals of the Rheumatic Diseases, 2018, 77, 1311-1317.	0.5	85
11	Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leukemia and Lymphoma, 2017, 58, 2633-2641.	0.6	19
12	Golimumab for the treatment of axial spondyloarthritis. Expert Opinion on Biological Therapy, 2017, 17, 129-133.	1.4	3
13	Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatology: Research and Reviews, 2017, Volume 9, 21-28.	0.8	41
14	Retrospective analysis of type 2 diabetes prevalence in a systemic sclerosis cohort from southern Italy: Comment on "Reduced incidence of Type 1 diabetes and Type 2 diabetes in systemic sclerosis: A nationwide cohort study―by Tseng et al., Joint Bone Spine 2016;83:307–13. Joint Bone Spine, 2016, 83, 611-612.	0.8	15
15	Improvements in diagnostic tools for early detection of psoriatic arthritis. Expert Review of Clinical Immunology, 2016, 12, 1209-1215.	1.3	26
16	Rheumatic manifestations of hepatitis C virus chronic infection: Indications for a correct diagnosis. World Journal of Gastroenterology, 2016, 22, 1405.	1.4	16
17	Pharmacological therapy of spondyloarthritis. Expert Opinion on Pharmacotherapy, 2015, 16, 1495-1504.	0.9	12
18	Relationship of Psoriatic Arthritis to Other Spondyloarthritides. Journal of rheumatology Supplement, The, 2015, 93, 33-35.	2.2	3

## MICHELE GILIO

#	Article	IF	CITATIONS
19	An update on the management of hepatitis C virus-related arthritis. Expert Opinion on Pharmacotherapy, 2014, 15, 2039-2045.	0.9	7
20	Follicular Bisection in Hair Restoration: In Vivo Experiment. Dermatologic Surgery, 2010, 36, 1484-1487.	0.4	1